Constantinidou, Anastasia Marcou, Yiola Toss, Michael S Simmons, Timothy Bernhisel, Ryan Hughes, Elisha Probst, Braden Meek, Stephanie Kakouri, Eleni Georgiou, Georgios
...
Published in
Clinical cancer research : an official journal of the American Association for Cancer Research
The EndoPredict prognostic assay is validated to predict distant recurrence and response to chemotherapy primarily in post-menopausal women with estrogen receptor-positive (ER+), HER2- breast cancer. This study evaluated the performance of EndoPredict in pre-menopausal women. Tumor samples from 385 pre-menopausal women with ER+, HER2- primary breas...
Taniguchi, Yuri Shimokawa, Tsuneo Takiguchi, Yuichi Misumi, Toshihiro Nakamura, Yukiko Kawashima, Yosuke Furuya, Naoki Shiraishi, Yoshimasa Harada, Toshiyuki Tanaka, Hisashi
...
Published in
Clinical cancer research : an official journal of the American Association for Cancer Research
The addition of cytotoxic chemotherapy to immune-checkpoint inhibitor (ICI) may enhance antitumor effects. We conducted an open-label randomized phase II/III study to evaluate nivolumab + docetaxel combination therapy in comparison with nivolumab monotherapy for previously treated ICI-naïve non-small cell lung cancer (NSCLC). The primary endpoint o...
Davar, Diwakar Zarour, Hassane M
Published in
Clinical cancer research : an official journal of the American Association for Cancer Research
Immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) proteins transformed the management of advanced cancers. Many tumor-intrinsic factors modulate immunological and clinical responses to such therapies, but ample evidence also implicates the gut microbiome in responses. The...
Serra, Violeta Wang, Anderson T Castroviejo-Bermejo, Marta Polanska, Urszula M Palafox, Marta Herencia-Ropero, Andrea Jones, Gemma N Lai, Zhongwu Armenia, Joshua Michopoulos, Filippos
...
Published in
Clinical cancer research : an official journal of the American Association for Cancer Research
PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique...
Pietzak, Eugene J Whiting, Karissa Srinivasan, Preethi Bandlamudi, Chaitanya Khurram, Aliya Joseph, Vijai Walasek, Aleksandra Bochner, Emily Clinton, Timothy Almassi, Nima
...
Published in
Clinical cancer research : an official journal of the American Association for Cancer Research
Identification of inherited germline variants can guide personalized cancer screening, prevention, and treatment. Pathogenic and likely pathogenic (P/LP) germline variants in cancer predisposition genes are frequent among patients with locally advanced or metastatic urothelial carcinoma, but their prevalence and significance in patients with non-mu...
Berger, Barry M Hanna, Glenn J Posner, Marshall R Genden, Eric M Lautersztain, Julio Naber, Stephen P Del Vecchio Fitz, Catherine Kuperwasser, Charlotte
Published in
Clinical cancer research : an official journal of the American Association for Cancer Research
Despite generally favorable outcomes, 15% to 25% of patients with human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma (OPSCC) will have recurrence. Current posttreatment surveillance practices rely on physical examinations and imaging and are inconsistently applied. We assessed circulating tumor tissue modified viral (TTMV)-HPV ...
Weber, Manuel Kersting, David Riemann, Burkhard Brandenburg, Tim Führer-Sakel, Dagmar Grünwald, Frank Kreissl, Michael C Dralle, Henning Weber, Frank Schmid, Kurt Werner
...
Published in
Clinical cancer research : an official journal of the American Association for Cancer Research
Restoration of iodine incorporation (redifferentiation) by MAPK inhibition was achieved in previously radioiodine-refractory, unresectable thyroid carcinoma (RR-TC). However, results were unsatisfactory in BRAFV600E-mutant (BRAF-MUT) RR-TC. Here we assess safety and efficacy of redifferentiation therapy through genotype-guided MAPK-modulation in pa...
Gazinska, Patrycja Milton, Charlotte Iacovacci, Jacopo Ward, Joseph Buus, Richard Alaguthurai, Thanussuyah Graham, Rosalind Akarca, Ayse Lips, Esther Naidoo, Kalnisha
...
Published in
Clinical Cancer Research
Purpose: To identify potential immune targets in post-neoadjuvant chemotherapy (NAC)–resistant triple-negative breast cancer (TNBC) and ER+HER2– breast cancer disease. Experimental Design: Following pathology review, 153 patients were identified as having residual cancer burden (RCB) II/III disease (TNBC n = 80; ER+HER2– n = 73). Baseline pre-NAC s...
Aggarwal, Rahul Starodub, Alexander N Koh, Brian D Xing, Guan Armstrong, Andrew J Carducci, Michael A
Published in
Clinical cancer research : an official journal of the American Association for Cancer Research
A phase Ib study (1604) was conducted to evaluate the safety and efficacy of GS-5829, an oral bromodomain and extraterminal inhibitor, alone and in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). A phase I study (1599) in solid tumors/lymphoma was also conducted. Men with confirmed mCRPC and disease progres...
Batra, Vandana Samanta, Minu Makvandi, Mehran Groff, David Martorano, Paul Elias, Jimmy Ranieri, Pietro Tsang, Matthew Hou, Catherine Li, Yimei
...
Published in
Clinical cancer research : an official journal of the American Association for Cancer Research
[131I]meta-iodobenzylguanidine ([131I]MIBG) is a targeted radiotherapeutic administered systemically to deliver beta particle radiation in neuroblastoma. However, relapses in the bone marrow are common. [211At]meta-astatobenzylguanidine ([211At] MABG) is an alpha particle emitter with higher biological effectiveness and short path length which effe...
